Pulmonologists' Opinion on the Use of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease Patients in Spain: A Cross-Sectional Survey

被引:2
作者
Miravitlles, Marc [1 ,2 ,15 ]
Gonzalez-Torralba, Fernando [3 ]
Represas-Represas, Cristina [4 ]
Pomares, Xavier [2 ,5 ,14 ]
Marquez-Martin, Eduardo [2 ,6 ]
Gonzalez, Cruz [7 ]
Amado, Carlos [8 ]
Forne, Carles [1 ,9 ,10 ]
Alonso, Soledad [11 ]
Alcazar, Bernardino [12 ]
Barrecheguren, Miriam [1 ]
Mirete, Juan Maria Jurado [13 ]
Naval, Elsa
机构
[1] Hosp Universitari Vall dHebron, Vall dHebron Barcelona Hosp Campus, Vall dHebron Inst Recerca VHIR, Pneumol Dept, Barcelona, Spain
[2] ISCIII, CIBER Enfermedades Respiratorias CIBERES, Madrid, Spain
[3] Hosp Univ Tajo, Pneumol Dept, Aranjuez, Spain
[4] Hosp Alvaro Cunqueiro, Pneumol Dept, Vigo, Spain
[5] Corporacio Sanitaria Parc Tauli, Pneumol Dept, Sabadell, Spain
[6] Hosp Univ Virgen Rocio, Med Surg Unit Resp Dis, Seville, Spain
[7] Hosp Clin Valencia, Pneumol Dept, Valencia, Spain
[8] Hosp Univ Marques Valdecilla, Pneumol Dept, Santander, Spain
[9] Heorfy Consulting, Lleida, Spain
[10] Univ Lleida, Basic Med Sci Dept, Lleida, Spain
[11] Hosp Univ Torrejon, Pneumol Dept, Torrejon De Ardoz, Spain
[12] Hosp Univ Virgen Nieves, Pneumol Dept, Granada, Spain
[13] GOC Hlth Consulting, Sci Dept, Barcelona, Spain
[14] Hosp Univ Ribera, Pneumol Dept, Alzira, Spain
[15] Hosp Universitari Vall dHebron, Pneumol Dept, Marc Miravitlles, P Vall dHebron 119-129, Barcelona 08035, Spain
关键词
COPD; exacerbation; bronchodilators; inhaled corticosteroids; eosinophils; withdrawal; COPD PATIENTS; EXACERBATIONS; WITHDRAWAL; RISK;
D O I
10.2147/COPD.S369118
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Introduction: Identifying the variables that guide decision-making in relation to the use of inhaled corticosteroids (ICS) can contribute to the appropriate use of these drugs. The objective of this study was to identify the clinical variables that physicians consider most relevant for prescribing or withdrawing ICS in COPD.Methods: A cross-sectional survey was conducted in Spain from November 2020 to May 2021. Therapeutic decisions on the use of ICS in 11 hypothetical COPD patient profiles were collected using an online survey answered by specialists with experience in the management of patients with COPD. Mixed-effects logistic regression was used to analyze the impact of patients' characteristics in the therapeutic decision for prescribing ICS or proceeding to its withdrawal.Results: A total of 74 pulmonologists agreed to collaborate in the survey and answered the questionnaire. The results showed great variability, with only 2 profiles achieving consensus for starting or withdrawing the treatment. The frequency and severity of exacerbations influenced the decision to prescribe ICS in a dose-response fashion (1 exacerbation odds ratio (OR) = 1.86, 95% confidence interval (CI) 1.02 to 3.43, two exacerbations OR = 11.6, 95% CI: 4.47 to 30.2 and three OR = 123, 95% CI: 25 to 601). Similarly, increasing blood eosinophils and history of asthma were associated with ICS use. On the other hand, pneumonia reduced the probability of initiating treatment with ICS (OR = 0.54 [0.29 to 0.98]). Lung function and dyspnea degree did not influence the clinician's therapeutic decision. The results for withdrawal of ICS were similar but in the opposite direction.Conclusion: In accordance with guidelines, exacerbations, blood eosinophils and history of asthma or pneumonia are the factors considered by pulmonologist for the indication or withdrawal of ICS. However, the agreement in prescription or withdrawal of ICS when confronted with hypothetical cases is very low, suggesting a great variability in clinical practice.
引用
收藏
页码:1577 / 1587
页数:11
相关论文
共 30 条
[11]   The Excessive Use of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease [J].
Izquierdo Alonso, Jose Luis ;
Rodriguez Glez-Moro, Jose Miguel .
ARCHIVOS DE BRONCONEUMOLOGIA, 2012, 48 (06) :207-212
[12]   Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies [J].
Loke, Yoon K. ;
Cavallazzi, Rodrigo ;
Singh, Sonal .
THORAX, 2011, 66 (08) :699-708
[13]   Clinical Management of COPD in a Real-World Setting. A Big Data Analysis [J].
Luis Izquierdo, Jose ;
Morena, Diego ;
Gonzalez, Yolanda ;
Manuel Paredero, Jose ;
Perez, Bernardino ;
Graziani, Desiree ;
Gutierrez, Matilde ;
Miguel Rodriguez, Jose .
ARCHIVOS DE BRONCONEUMOLOGIA, 2021, 57 (02) :94-100
[14]   Withdrawal of inhaled corticosteroids versus continuation of triple therapy in patients with COPD in real life: observational comparative effectiveness study [J].
Magnussen, Helgo ;
Lucas, Sarah ;
Lapperre, Therese ;
Quint, Jennifer K. ;
Dandurand, Ronald J. ;
Roche, Nicolas ;
Papi, Alberto ;
Price, David ;
Miravitlles, Marc .
RESPIRATORY RESEARCH, 2021, 22 (01)
[15]   Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPD [J].
Magnussen, Helgo ;
Disse, Bernd ;
Rodriguez-Roisin, Roberto ;
Kirsten, Anne ;
Watz, Henrik ;
Tetzlaff, Kay ;
Towse, Lesley ;
Finnigan, Helen ;
Dahl, Ronald ;
Decramer, Marc ;
Chanez, Pascal ;
Wouters, Emiel F. M. ;
Calverley, Peter M. A. ;
Chia, M. ;
Peters, M. ;
Polasek, J. ;
Sajkov, D. ;
Seale, P. ;
Wheatley, J. ;
Bedert, L. ;
Driesen, P. ;
Fievez, P. ;
Flemale, A. ;
Martinot, J-B ;
Mentens, Y. ;
Ninane, V ;
Peche, R. ;
Plas, B. ;
van Zandweghe, L. ;
Adalberto, R. ;
Carmo Moreira, M. A. ;
Fritscher, C. ;
Gondim, H. ;
Jardim, J. R. B. ;
Dancheva, A. ;
Kostov, K. ;
Lllieva-Fartunova, V ;
Metev, H. ;
Osmanliev, D. ;
Palaveev, Rashkov K. ;
Taseva, M. ;
Troshanova, E. ;
Bai, C. ;
Baiqiang, C. ;
Li, H. ;
Lin, Y. ;
Tang, Y. ;
Wu, Y. ;
Xin, J. ;
Yao, W. .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (14) :1285-1294
[16]   Systematic review on long-term adverse effects of inhaled corticosteroids in the treatment of COPD [J].
Miravitlles, Marc ;
Auladell-Rispau, Ariadna ;
Monteagudo, Monica ;
Carlos Vazquez-Niebla, Juan ;
Mohammed, Jibril ;
Nunez, Alexa ;
Urrutia, Gerard .
EUROPEAN RESPIRATORY REVIEW, 2021, 30 (160)
[17]   Spanish COPD Guidelines (GesEPOC) 2021: Updated Pharmacological treatment of stable COPD [J].
Miravitlles, Marc ;
Calle, Myriam ;
Molina, Jesus ;
Almagro, Pere ;
Gomez, Jose-Tomas ;
Antonio Trigueros, Juan ;
Cosio, Borja G. ;
Casanova, Ciro ;
Luis Lopez-Campos, Jose ;
Antonio Riesco, Juan ;
Simonet, Pere ;
Rigau, David ;
Soriano, Joan B. ;
Ancochea, Julio ;
Jose Soler-Cataluna, Juan .
ARCHIVOS DE BRONCONEUMOLOGIA, 2022, 58 (01) :69-81
[18]   GesEPOC 2021: One More Step Towards Personalized Treatment of COPD [J].
Miravitlles, Marc ;
Calle, Myriam ;
Soler-Cataluna, Juan Jose .
ARCHIVOS DE BRONCONEUMOLOGIA, 2021, 57 (01) :9-10
[19]   Blood Eosinophil Counts and Their Variability and Risk of Exacerbations in COPD: A Population-Based Study [J].
Miravitlles, Marc ;
Monteagudo, Monica ;
Solntseva, Iryna ;
Alcazar, Bernardino .
ARCHIVOS DE BRONCONEUMOLOGIA, 2021, 57 (01) :13-20
[20]   A proposal for the withdrawal of inhaled corticosteroids in the clinical practice of chronic obstructive pulmonary disease [J].
Miravitlles, Marc ;
Cosio, Borja G. ;
Arnedillo, Aurelio ;
Calle, Myriam ;
Alcazar-Navarrete, Bernardino ;
Gonzalez, Cruz ;
Esteban, Cristobal ;
Antonio Trigueros, Juan ;
Rodriguez Gonzalez-Moro, Jose Miguel ;
Quintano Jimenez, Jose Antonio ;
Baloira, Adolfo .
RESPIRATORY RESEARCH, 2017, 18